Drug General Information (ID: DDID2BSMKF)
  Drug Name Capreomycin Drug Info Amikacin Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antibiotics Antibiotics
  Structure

 Mechanism of Capreomycin-Amikacin Interaction (Severity Level: Major)
     Additive neuromuscular blocking effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Capreomycin Amikacin
      Mechanism 1 Neuromuscular blocking effects Neuromuscular blocking effects
      Key Mechanism Factor 1
Factor Name Neuromuscular blocking effects
Factor Description Neuromuscular blocking agents cause paralysis of affected skeletal muscles by blocking postsynaptic acetylcholine (Nm) receptors, thereby blocking neuromuscular signaling at the neuromuscular junction. Neuromuscular blocking agents can cause the following side effects: muscle paralysis, jaw stiffness, and shortness of breath. Concomitant use of drugs with neuromuscular blocking activity may result in severe and/or prolonged respiratory depression.
      Mechanism Description
  • Additive neuromuscular blocking effects by the combination of Capreomycin and Amikacin 
     Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Capreomycin Amikacin
      Mechanism 2 Nephrotoxicity Nephrotoxicity
      Key Mechanism Factor 2
Factor Name Nephrotoxicity
Factor Description The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood.
      Mechanism Description
  • Increased risk of nephrotoxicity by the combination of Capreomycin and Amikacin 

Recommended Action
      Management This combination should be avoided concurrently or sequentially. If coadministration is medically necessary, patients should be closely monitored for development of toxicity, including renal function tests, respiratory function, and vestibular and audiometric tests.

References
1 Product Information. Arikayce (amikacin liposome). Insmed Incorporated, Bridgewater, NJ.
2 Product Information. Garamycin (gentamicin). Schering-Plough Corporation, Kenilworth, NJ.
3 Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL "Reversible respiratory paralysis associated with polymyxin therapy." Ann Intern Med 68 (1968): 318-27.[PMID: 4306125]